Effect of vaccination on nasopharyngeal pneumococcus serotype

comparison of pneumococcal serotypes separated from nasopharynx in children 6 months to 5 years old referred to before and after pneumococcal vaccination

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012080510497N1

Enrollment

Registered

2012-12-29

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia due to Streptococcus pneumoniae. Pneumonia (acute) (double) (migratory) (purulent) (septic) (unresolved) - in (due to) - Streptococcus - pneumoniae

Interventions

Injection of one dose (0.5 ml) Prevnar 13 Produced by Pfizer company intramuscular (thigh in infants or upper arm in children). Comparing the pharyngeal colonization of pnemococus before and after vac

Prevention

Eligibility

Sex/Gender

All

Age

1 Years to 5 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All children with age of 6 months to 5 years referred to pediatric clinics of Rasoul Akram Hospital after filling the consent letter by their patents. Exclusion criteria: Previous disease including diabetes, spina bifida, asplenia, sickle cell anemia, innate or acquired immune system deficiency, previous cochlear implantation, chronic cardiac and pulmonary disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Colonization of organism. Timepoint: On month before and one year after injection of Prevnar vaccine. Method of measurement: Culture.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamileh Noorbaksh

Research Center for Pediatric Infectious Diseases

cpidir@gmail.com+98 21 6651 6049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026